3586 results about "Antigen" patented technology

The invention belongs to the technical field of software development and testing, and discloses an artificial intelligence-based software development automatic test case generation system, which is characterized in that an immune heuristic case self-repairing module is adopted, defects are regarded as antigens, antibody cases capable of being self-updated are generated by using a clone selection algorithm, and a gene rearrangement mechanism is automatically triggered when an interface is changed, so that the test efficiency is improved. The details of the use case are adjusted while the core detection logic is reserved; compared with a traditional method, the mechanism can realize use case dynamic adaptation without manual intervention, the maintenance workload is remarkably reduced, and the method is particularly suitable for a complex software system with frequent iteration; the space-time coupling test scene generation engine fuses dynamic scenes such as interaction and state transition of a module and short-time operation after precise coverage login by using a space-time convolutional network; the cross-dimension holographic use case synthesis module integrates multi-source data such as codes, hardware and user behaviors through tensor decomposition to generate a composite use case; functions and performance of software in a complex scene can be comprehensively verified, and test blind areas are remarkably reduced.

The invention discloses a hybridoma cell strain, a monoclonal antibody, a linear epitope antigen and application thereof, and relates to the field of genetic engineering, in particular to a hybridoma cell strain, a monoclonal antibody, a linear epitope antigen and application thereof. The preservation number of the hybridoma cell strain P27-A1 is CGMCC (China General Microbiological Culture Collection Center) No. 46352. The hybridoma cell strain P27-A1 is prepared from feline leukemia virus p27, and a monoclonal antibody secreted by the hybridoma cell strain P27-A1 recognizes a linear epitope antigen of feline leukemia virus p27 protein; the kit for the feline leukemia virus p27 comprises the monoclonal antibody A1 secreted by the hybridoma cell strain P27-A1. The monoclonal antibody secreted by the hybridoma cell strain can greatly improve the sensitivity of the p27 protein for detecting feline leukemia virus. The invention provides the monoclonal antibody secreted by the hybridoma cell strain for identification, and the monoclonal antibody can be used for preparing a diagnostic kit such as a colloidal gold test strip.

The invention belongs to the technical field of biology, and particularly relates to a group of paired monoclonal antibodies for resisting H9N2 subtype avian influenza viruses and a surface enhanced Raman spectroscopy rapid detection test strip established based on the antibodies. The paired monoclonal antibody comprises a labeled antibody 1E9 and a capture antibody 3C10 which are prepared by taking hemagglutinin protein of the H9N2 subtype avian influenza virus as antigens and can be specifically combined with the H9N2 subtype avian influenza virus. According to the invention, an SERS (Surface Enhanced Raman Scattering) probe Au-coated Pt-4ATP is used as a marker and is coupled with a labeled antibody 1E9 to prepare a labeled probe, and the labeled probe is paired with a capture antibody 3C10 to establish an SERS immunochromatography test strip. The test strip has a colorimetric and Raman dual interpretation mode, can be used for qualitative and quantitative detection, has the advantages of strong specificity, high sensitivity, good repeatability and stability and the like, is simple and rapid in clinical detection operation, and provides reliable technical support for on-site rapid screening of subtype viruses.

The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.

This invention discloses a monoclonal antibody against human hepatitis B e antigen and its application, relating to the field of hepatitis B detection technology. In the heavy chain variable region of the monoclonal antibody, the amino acid sequences of the complementarity-determining regions (CDR1-3) are as shown in SEQ ID NO. 1-3 or have at least 95% homology with the sequences shown in SEQ ID NO. 1-3; in the light chain variable region, the amino acid sequences of the complementarity-determining regions (CDR1 and CDR3) are as shown in SEQ ID NO. 4 and 5 or have at least 95% homology with the sequences shown in SEQ ID NO. 4 and 5, and the amino acid sequence of the complementarity-determining region (CDR2) is FAS. The monoclonal antibody provided by this invention can effectively recognize natural hepatitis B e antigen, and the titer of the supernatant from B cell culture can reach 1:10000, making it fully applicable to the detection and research of human hepatitis B e antigen. The chemiluminescent reagent prepared using the monoclonal antibody described in this invention has advantages such as high specificity, strong anti-interference ability, high detection sensitivity, and good stability, with almost no missed detections, and can replace imported reagents.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting canine parainfluenza virus NP protein and application thereof. The combination is composed of monoclonal antibodies 5H10 and 1H7, 5H10 is used as a coating antibody, and 1H7 is used for colloidal gold labeling, so that efficient and specific sandwich detection of CPIV / NP antigen can be realized. The variable region CDR sequences of the heavy chains and light chains of the two antibodies are clear (SEQ ID NO. 1-12). The application also provides a rapid detection test strip based on the antibody combination, which can be used for on-site screening, early diagnosis and epidemiological monitoring of canine parainfluenza virus, solves the problem that existing detection technologies lack high-specificity recognition tools, and has a good application prospect.

The present invention is directed to an isolated antibody or antigen binding fragment thereof binding specifically to human NPTXR with the amino acid sequence of SQ ID NO: 1, wherein the isolated antibody or antigen binding fragment comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 4; HCDR2 comprises the amino acid sequence of SEQ ID NO: 5; and HCDR3 comprises the amino acid sequence of SEQ ID NO: 6; and wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 7; LCDR2 comprises the amino acid sequence of SEQ ID NO: 8; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 9.

The invention relates to the technical field of repair materials, and particularly discloses an extracellular matrix fiber material as well as a preparation method and application thereof. The invention discloses a preparation method of an extracellular matrix fiber material. The preparation method comprises the following steps: taking animal tissues, and carrying out virus inactivation, decellularization and antigen removal, degreasing, drying, grinding and sterilization; the decellularization and antigen removal method comprises the following specific steps: sequentially soaking a sample with a surfactant solution for h; then, soaking treatment is carried out by adopting a salt-alkali solution which contains 0.05-3 mol / L of salt and has the pH value of 8-11; then carrying out soaking treatment by adopting a 0.1-1wt% enzyme solution; and in degreasing, one or more of normal hexane, trichloromethane, dichloromethane, methanol, ethanol, acetone, diethyl ether and ethyl acetate are used for soaking the sample. According to the technical scheme, the ECM powder particle material with high growth factor content is prepared.

The invention discloses a recombinant protein for detecting a para-tumor Yo antibody through a CBA method and application, and belongs to the technical field of biomedical engineering.The amino acid sequence of the recombinant protein sequentially comprises a secretory signal peptide, a CDR2 protein partial sequence, a CDR2L protein partial sequence, a transmembrane region and a fluorescent label, and the secretory signal peptide is human albumin signal peptide ALB; the transmembrane region is a CD8a hinge; and the fluorescent label is mCherry. A novel recombinant protein which can be stably over-expressed on a cell membrane of an eukaryotic cell is constructed by intercepting specific partial sequences of CDR2 protein and CDR2L protein and redesigning and fusing a fluorescent label by using a secretory signal peptide, a transmembrane sequence and a connecting peptide, and the recombinant protein retains respective core antigen regions of the CDR2 protein and the CDR2L protein, so that the specific partial sequences of the CDR2 protein and the CDR2L protein can be stably over-expressed on the cell membrane of the eukaryotic cell. The kit can effectively overcome the defects in the aspects of sensitivity and specificity, and when a CBA method is adopted for detection, the detection rate of the para-tumor Yo antibody can be remarkably increased, and the false positive rate is reduced, so that the requirements of clinical detection are better met.

The present invention provides a rabies virus G protein antigen epitope targeting completely human monoclonal antibody and applications thereof, the completely human monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP, and the light chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP. The amino acid sequences of the three complementary determining regions of the light chain variable region are respectively as follows: QGISND, ATS and LQDYEFPLT. The fully human monoclonal antibody has efficient and broad-spectrum anti-rabies virus neutralizing activity, is high in expression, fully human-derived and good in stability, and can be used for preparing rabies virus detection products or drugs for preventing and treating rabies.

The invention provides a bovine parainfluenza virus type 3 QL3 strain, and the preservation number of the bovine parainfluenza virus type 3 QL3 strain is CGMCC No.46469. The invention also provides a bovine parainfluenza inactivated vaccine containing the bovine parainfluenza virus type 3 QL3 strain and purified F protein and HN protein of the QL3 strain. The novel bovine parainfluenza virus type 3 inactivated vaccine is obtained by optimizing the antigen components of the bovine parainfluenza virus type 3 inactivated vaccine, and high-level neutralizing antibodies can be generated after immunizing cattle; the safety of the vaccine is improved through process optimization. Safety and potency test results show that after the inactivated vaccine is used for immunizing cattle, no adverse reaction exists, and high-level neutralizing antibodies are generated. Results show that the immune effect of the bovine parainfluenza virus type 3 inactivated vaccine can be improved.

The invention provides a cancer risk level distinguishing method and system, and relates to the technical field of prostate cancer, the method comprises the following steps: obtaining personal information of a screening object and a prostate specific antigen inspection result of the screening object; based on the personal information of the screening object and the prostate specific antigen inspection result of the screening object, determining a risk value of antigen inspection of the screening object; if the risk value of the antigen examination of the screening object is greater than a preset threshold value, obtaining a prostate magnetic resonance scanning image of the screening object; constructing a graph structure; processing the graph structure based on a graph convolutional network to determine prostate cancer analysis information; based on the prostate magnetic resonance scanning image of the screened object and the prostate cancer analysis information, using a generative adversarial network to generate a prostate cancer simulated growth video; the prostate cancer risk level is determined based on the prostate cancer simulated growth video, and the method can accurately evaluate the risk of prostate cancer.

The invention provides an antibody drug conjugate property prediction method based on multi-modal fusion, and belongs to the field of bioinformatics. The method comprises the following steps: firstly, explicitly modeling sequence position information through sine position coding; secondly, introducing a bidirectional cross attention mechanism to establish interaction between a light chain and a heavy chain and alignment between an antigen and an antibody; thirdly, the integrated graph neural network reconstructs the adjacency relation according to the attention weight, and topological features are extracted; and finally, in combination with a double-stage self-adaptive refining module, two-stage treatment of alignment and refining is realized, and each modal feature contribution is adjusted in a self-adaptive manner. And meanwhile, the sequence robustness is improved through Mask perception feature extraction, and the interpretability analysis of the key binding sites is realized through the attention weight. The method can significantly improve the prediction accuracy, and can be widely applied to cancer targeted therapy and drug design optimization.

The application discloses an electrochemiluminescence immunosensor for detecting interleukin-1 beta and a preparation method and application thereof, and comprises a three-electrode system of a working electrode, a reference electrode and a counter electrode; the working electrode is a modified electrode of CoAl layered double hydroxide, is loaded with platinum nanoparticles after being etched by alkali, and is obtained by fixing interleukin-1 beta antibodies and blocking non-specific sites; and a solution containing luminol is used as an electrolyte during detection of the immunosensor. The working electrode of the immunosensor takes oxygen-rich vacancy CoAl layered double hydroxide as a substrate, combines with platinum nanoparticles to realize EMSI effect, significantly enhances the electrochemiluminescence signal of a luminol-dissolved oxygen system, realizes quantitative detection of IL-1 beta by combining with specific antigen-antibody recognition, and has the characteristics of strong anti-interference ability, fast detection speed and good stability.

The invention discloses an anti-SLC3A2 antibody or an antigen binding fragment thereof, the antibody comprises a heavy chain variable region and further comprises a light chain variable region, and the antibody specifically recognizes SLC3A2. Also disclosed are conjugates comprising an antibody against SLC3A2 or an antigen-binding fragment thereof, and the use of the antibodies of the disclosure in the treatment of disease.

Provided is an ultrasensitive method for measuring an anti-drug antibody that is simpler and less expensive than conventional methods. Provided is an ultrasensitive method for measuring an analyte using a capture probe and an assist probe and adopting an improved PALSAR method. By using the capture probe and the assist probe and adopting the improved PALSAR method in a double antigen bridging immunoassay, ultrasensitive measurement of an anti-drug antibody can be performed simply and inexpensively.

The invention provides an immunomagnetic bead, a preparation method and a detection reagent. The preparation method comprises the following steps: preparing a modified magnetic bead containing a dibenzocyclooctyne group; protein and a coupling agent containing azide groups are sequentially dissolved in a second coupling buffer solution to react, modified protein containing azide groups is obtained, the final concentration of the reacted protein is 0.5-5 mg / mL, and the final concentration of the coupling agent is 0.05-5 mM; and mixing the modified magnetic beads and the modified protein according to an addition ratio of 1mg: (1-40) nmol, and reacting to obtain the immunomagnetic beads. According to the present invention, the immunomagnetic bead preparation method has advantages of high coupling efficiency, small inter-batch difference, strong specificity and difficult aggregation during the preparation process, such that the accurate detection of the antigen concentration is achieved so as to solve the defects of low coupling efficiency, large inter-batch difference and easy aggregation existing in the immunomagnetic bead preparation method in the related technology.

The invention relates to the field of immunology, and particularly discloses a hepatitis B virus specific TCR combination and application, the hepatitis B virus specific TCR combination is used for recognizing HBV antigen epitopes, the hepatitis B virus specific TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The invention relates to a monoclonal antibody DIDA55 aiming at hog cholera virus, and a preparation method and application thereof, belonging to the field of medical preparations. The monoclonal antibody DIDA55 or an antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, amino acid sequences of LCDR1, LCDR2 and LCDR3 in a light chain variable region of the antibody are shown as 24th to 34th, 50th to 56th and 89th to 97th in SEQ ID No: 4; amino acid sequences of HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of the antibody are shown as the 31st to 35th, the 50th to 65th and the 95th to 102th of SEQ ID No: 5. The monoclonal antibody provided by the invention can be used in the fields of swine fever E2 protein labeled subunit vaccine immunity, serological diagnosis of wild strains, swine fever vaccine immune effect evaluation, related experiments and the like, and provides antibody resources for prevention, control and purification of CSF.

The present disclosure relates to pharmaceutical compositions comprising [61Cu]Cu-NODAGA-PSMA I&T or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a prostate-specific membrane antigen (PSMA)-expressing tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

The present disclosure relates to the synthesis of prostate-specific membrane antigen (PSMA) ligands useful in the treatment of diseases such as cancer. In particular, the present disclosure relates to methods for synthesizing PSMA ligands having a glutamic acid-urea-lysine (GUL) moiety and a chelator that may include a radiometal.

The invention discloses a triiodothyronine dissociation agent, a detection kit, a preparation method of the triiodothyronine dissociation agent and application of the triiodothyronine dissociation agent and the detection kit, and the triiodothyronine dissociation agent comprises 10-100 mM of acetic acid-sodium acetate buffer solution, 0.05-1 g / L of ethylene diamine tetraacetic acid disodium salt, 1-10 g / L of perfluoroalkyl ethyl methacrylate, 0.2-1 mL / L of Tween-20 and 0.2-2 mL / L of ProClin 300, the pH (Potential of Hydrogen) of the triiodothyronine dissociation agent is 5.5 + / -1; the kit comprises a triiodothyronine dissociation agent and a reagent strip. According to the present invention, the two sites can be specifically recognized, the sensitivity and the specificity are high, the high-specificity detection on the specific antigen can be achieved, and the low-end sensitivity is high; meanwhile, the interference problem of rare earth europium during detection of triiodothyronine can be solved, and the accuracy of a detection result is further improved.

The invention relates to the technical field of biological medicines and vaccines, in particular to a nano-selenium modified liposome as well as a preparation method and application thereof. The nano-selenium modified lipidosome disclosed by the invention comprises a lipidosome and nano-selenium. Wherein the nano-selenium is modified on the surface of the liposome; the liposome is composed of cholesterol, phospholipid, and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000. The nano-selenium modified liposome can be suitable for different treatment scenes, becomes a multifunctional drug delivery platform, has the characteristics of long circulation, good biocompatibility, high drug loading rate, good stability, increase of retention time of a treatment drug in a body and the like, can be directly entrapped with an antigen, can also be cooperatively combined with a drug and a vaccine, and has a wide application prospect. The defects of low bioavailability, poor stability, toxic and side effects and the like of the existing medicinal preparation are overcome, and the immunotherapy effect is remarkably enhanced while the treatment medicine in the liposome is promoted to achieve a remarkable slow release effect.

The invention relates to the technical field related to immunological detection, in particular to a mouse anti-porcine herpesvirus type 1 gE monoclonal antibody as well as an immunogen and application of the mouse anti-porcine herpesvirus type 1 gE monoclonal antibody. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: GFSLSTSGMG, IVWGSETGRVTISRDNSK and VRYYDGDDD, and the amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: KSSQSLLYSDGKTFLN, LGSNRAS and SSLPHED. The monoclonal antibody can be specifically combined with gE proteins of all subtypes of the porcine herpesvirus type 1, and a porcine herpesvirus type 1 detection kit prepared from the monoclonal antibody has the advantages of high sensitivity, strong specificity, wide detection range, short detection time and the like.

The invention discloses a coal mill internal multi-source heterogeneous data fusion early warning method and system, and belongs to the technical field of industrial equipment fault diagnosis. The method aims at solving the technical problems that an existing coal mill early warning method is insufficient in multi-source data fusion, poor in working condition adaptability, low in early warning accuracy and lack of fault tracing and accurate control. According to the technical scheme, the method comprises the steps that structured process parameter data and unstructured physical field data of the coal mill are obtained; constructing a digital antigen vector representing a running state; constructing an autologous space based on the historical health data, and generating a dynamic immunodetector set covering a non-autologous space; calculating the Euclidean distance between the digital antigen vector and the detector and a danger signal index; early warning is triggered through cooperative judgment, feedback control is executed, and a fault source is positioned in combination with fault tracing. The device state can be comprehensively represented, the working condition adaptability and the early warning accuracy are improved, accurate fault positioning and control are achieved, and the device maintenance cost is reduced.

Disclosed herein are systems, methods, and compositions for treating a subject diagnosed with, or suffering from cancer. In some embodiments, the method comprises determining whether a tumor sample from the subject includes a cytotoxic gene signature, and treating the subject based on the determination. In some embodiments, the subject has or is suspected of having a loss of heterozygosity in human leukocyte antigen (HLA) class I genes. In some embodiments, the therapy comprises one or more checkpoint inhibitors. In some embodiments, the cancer is colorectal, uterine, stomach, lung, skin, head or neck, or non-small cell lung carcinoma.

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.

The invention relates to a method for stimulating an immune response by intramuscular injection of an artificial nucleic acid molecule comprising an open reading frame encoding an antigen and a 3′-UTR comprising at least two poly(A) sequences. The method may yield an increased immune response to the antigen or an increased neutralizing antibody response to the antigen.